{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:07:34Z","timestamp":1782799654940,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.bcp.2010.02.019","type":"journal-article","created":{"date-parts":[[2010,3,4]],"date-time":"2010-03-04T14:41:00Z","timestamp":1267713660000},"page":"31-38","source":"Crossref","is-referenced-by-count":16,"title":["Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment"],"prefix":"10.1016","volume":"80","author":[{"given":"Sandra A.","family":"Bright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Campiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Clive","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Zisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2010.02.019_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2001.1.87","article-title":"Chronic myelogenous leukemia","volume":"1","author":"Druker","year":"2001","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bcp.2010.02.019_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-138-10-200305200-00010","article-title":"Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics","volume":"138","author":"Kurzrock","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2010.02.019_bib3","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.02.019_bib4","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.02.019_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2010.02.019_bib6","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.02.019_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2010.02.019_bib8","first-page":"591","article-title":"New combination therapies with cell-cycle agents","volume":"9","author":"Deep","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.bcp.2010.02.019_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3565(24)39202-X","article-title":"Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents","volume":"293","author":"Zisterer","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2010.02.019_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29659-2","article-title":"Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl","volume":"296","author":"Mc Gee","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2010.02.019_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/mol.105.021204","article-title":"Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines","volume":"70","author":"Mulligan","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2010.02.019_bib12","doi-asserted-by":"crossref","first-page":"18383","DOI":"10.1074\/jbc.M112058200","article-title":"Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells","volume":"277","author":"Mc Gee","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2010.02.019_bib13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.104.067561","volume":"310","author":"Mc Gee","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2010.02.019_bib14","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1158\/0008-5472.CAN-09-0131","article-title":"The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia","volume":"69","author":"McElligott","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib15","doi-asserted-by":"crossref","unstructured":"Bright SA, McElligott AM, O\u2019Connell JW, O\u2019Connor L, Carroll P, Campiani G, et al. Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo; 2010 (unpublished results).","DOI":"10.1038\/sj.bjc.6605670"},{"key":"10.1016\/j.bcp.2010.02.019_bib16","first-page":"1357","article-title":"The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo","volume":"14","author":"Greene","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bcp.2010.02.019_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.106.116640","article-title":"STI-571 enhances the apoptotic efficacy of PBOX-6, a novel microtubule targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells","volume":"321","author":"Greene","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2010.02.019_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006353008903","article-title":"Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials","volume":"17","author":"Senderowicz","year":"1999","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bcp.2010.02.019_bib19","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-040020","article-title":"Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol","volume":"10","author":"Shapiro","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib20","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","article-title":"Targeting the cell cycle: a new approach to cancer therapy","volume":"23","author":"Schwartz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib21","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/annonc\/mdg343","article-title":"Phase II study of flavopiridol in patients with advanced colorectal cancer","volume":"14","author":"Aklilu","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","article-title":"Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study","volume":"18","author":"Stadler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-03-0050","article-title":"A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer","volume":"10","author":"Liu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib24","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.2001.19.7.1985","article-title":"Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma","volume":"19","author":"Schwartz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CCO.0b013e3282efb9da","article-title":"Flavopiridol in the treatment of chronic lymphocytic leukemia","volume":"19","author":"Christian","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib26","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia","volume":"113","author":"Phelps","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2010.02.019_bib27","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1158\/1078-0432.CCR-07-0381","article-title":"Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia","volume":"13","author":"Karp","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib28","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-07-1218","article-title":"Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors","volume":"13","author":"Fornier","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib29","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-04-0025","article-title":"Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer","volume":"10","author":"Tan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3816\/CLC.2008.n.024","article-title":"Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer","volume":"9","author":"George","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.bcp.2010.02.019_bib31","doi-asserted-by":"crossref","first-page":"13103","DOI":"10.1073\/pnas.240390697","article-title":"Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin","volume":"97","author":"O\u2019Connor","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2010.02.019_bib32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1535-7163.MCT-05-0436","article-title":"Targeted therapy by disabling crossroad signaling networks: the survivin paradigm","volume":"5","author":"Altieri","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2010.02.019_bib33","first-page":"3375","article-title":"Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration","volume":"57","author":"Bible","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib34","first-page":"1876","article-title":"Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells","volume":"7","author":"Motwani","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib35","first-page":"924","article-title":"Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells","volume":"6","author":"Motwani","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib36","first-page":"230","article-title":"Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis","volume":"63","author":"Wall","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib37","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib","volume":"105","author":"O\u2019Hare","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2010.02.019_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.bcp.2010.02.019_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bcp.2008.10.008","article-title":"The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells","volume":"77","author":"Bright","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2010.02.019_bib40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1042\/bst0290704","article-title":"Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents","volume":"29","author":"Zisterer","year":"2001","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bcp.2010.02.019_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/mol.107.039024","article-title":"BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines","volume":"73","author":"Greene","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2010.02.019_bib42","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1074\/jbc.M310947200","article-title":"Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2\/M arrest","volume":"279","author":"Ling","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2010.02.019_bib43","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib44","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","article-title":"Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors","volume":"15","author":"Satoh","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bcp.2010.02.019_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2007.08.074","article-title":"Phase I\/II clinical safety studies of terameprocol vaginal ointment","volume":"107","author":"Khanna","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bcp.2010.02.019_bib46","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S1471-4914(02)02308-0","article-title":"Complexities in the development of cyclin-dependent kinase inhibitor drugs","volume":"4","author":"Sausville","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bcp.2010.02.019_bib47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","article-title":"Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia","volume":"96","author":"Kitada","year":"2000","journal-title":"Blood"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295210001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295210001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:22:38Z","timestamp":1739924558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295210001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0006295210001619"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2010.02.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}